Genmab tops STOXX 600 after promising cancer drug data

** Shares in Genmab GMAB.CO rise around 13% hitting top of STOXX 600 .STOXX index after the Danish biotech reported encouraging follow-up data from a mid-stage trial of an experimental colorectal cancer treatment

** Genmab said its experimental colorectal cancer treatment petosemtamab showed encouraging response rates, with promising depth and durability of response in first- and second-line metastatic disease

** J.P.Morgan lifts Genmab to "overweight" from "neutral" on strong drug pipeline

** The broker expects positive data for petosemtamab noting it "should continue to improve confidence in a strong mid-teens Revenue growth story"

** It says upgraded peak sales forecasts for ovarian cancer therapy Rina-S largely reflect unprecedented late-stage trial efficacy in progression-free and overall survival rate

** JPM lifts its peak sales estimates for blood cancer treatment Epkinly to $2.5 billion, citing reduced risks following strong trial benefits

** The stock is on a 3.5-year high